A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease

Solvay Pharmaceuticals11 个研究点分布在 3 个国家开始时间: 2005年10月1日最近更新: 2009年1月30日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Solvay Pharmaceuticals
试验地点: 11

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations. Patients (outpatients) will be randomized to one of three different treatment arms.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 30 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients who have signed an informed consent; diagnosis of idiopathic PD.
•Presence of recognizable "on" and "off" stages
•Minimum hours of "off" time per day of 2.5 hours
•Able to keep diaries.

排除标准

•Unclear diagnosis or a suspicion of other parkinsonian syndromes
•Have undergone surgical treatment for PD
•History of non-response to L-dopa.

研究者

发起方

Solvay Pharmaceuticals

申办方类型

Industry

研究点 (11)

Loading locations...

相似试验

撤回

3 期

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsParkinson's Disease

NCT02782481NeuroDerm Ltd.

已完成

3 期

MPC-004 for the Treatment of an Acute Gout FlareGout

NCT00506883Takeda185

已完成

2 期

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionSevere Postpartum Depression

NCT02614547Supernus Pharmaceuticals, Inc.21

招募中

1 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by VirusesSevere Viral Pneumonia(Not Include COVID-19)

NCT06693362Ruijin Hospital60

招募中

1 期

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaTardive Dyskinesia (TD)

NCT06731868Luye Pharma Group Ltd.120